Sagar Lonial, MD, FACP, FASCO, discusses findings from the CC-220-MM-001 trial of iberdomide plus daratumumab and dexamethasone in newly diagnosed myeloma.
Exploring CELMoDs in Multiple Myeloma Management
Rahul Banerjee, MD, FACP, discusses the ongoing investigations of mezigdomide and CELMoDs in multiple myeloma.
Dr Banerjee discussed the potential of CELMoDs for multiple myeloma management, highlighting their superior efficacy and safety compared with IMiDs.
Joshua Richter, MD, elaborates on the best scenarios for certain CELMoD-based treatments for patients with multiple myeloma.
Joshua Richter, MD, discusses the exploration of CELMoDs in the treatment of patients with multiple myeloma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
3
Oncology Fellows Presents a New Drug Cheat Sheet for Fellows
4
Third NDA for Rivoceranib/Camrelizumab Is Resubmitted to FDA for Unresectable HCC
5